B cell

European Wellness Shines at AMWC 2024 in Monaco, with Prof. Dr Mike Chan and Prof. Dr Roni Moya as Faculty's Stem Cells Speakers

Retrieved on: 
Tuesday, April 2, 2024
Health, B cell, Longevity, Biotechnology, Patient, Research, Stem cell, Safety, Peptide, Medicine

As 2 of 3 of the event faculty's main stem cells speakers, EWBG's Prof. Dato' Sri Dr Mike Chan and Prof. Dr Roni Moya shed light on the event, which is well-known for bringing together the world's leading specialists in aesthetic and anti-ageing medicine.

Key Points: 
  • As 2 of 3 of the event faculty's main stem cells speakers, EWBG's Prof. Dato' Sri Dr Mike Chan and Prof. Dr Roni Moya shed light on the event, which is well-known for bringing together the world's leading specialists in aesthetic and anti-ageing medicine.
  • They wowed delegates with their pioneering research and clinical innovations in bioregenerative medicine, putting EWBG at the forefront of the industry.
  • Mike Chan, known for his innovative pioneering work in stem cells and bioregenerative medicine, presented his most recent research discoveries, promising to transform how age-related illnesses are treated.
  • The presence of the 2 prominent speakers at AMWC 2024 demonstrates EWBG's dedication to advancing medical sciences for the benefit of humanity.

European Wellness Shines at AMWC 2024 in Monaco, with Prof. Dr Mike Chan and Prof. Dr Roni Moya as Faculty's Stem Cells Speakers

Retrieved on: 
Tuesday, April 2, 2024
Health, B cell, Longevity, Biotechnology, Patient, Research, Stem cell, Safety, Peptide, Medicine

As 2 of 3 of the event faculty's main stem cells speakers, EWBG's Prof. Dato' Sri Dr Mike Chan and Prof. Dr Roni Moya shed light on the event, which is well-known for bringing together the world's leading specialists in aesthetic and anti-ageing medicine.

Key Points: 
  • As 2 of 3 of the event faculty's main stem cells speakers, EWBG's Prof. Dato' Sri Dr Mike Chan and Prof. Dr Roni Moya shed light on the event, which is well-known for bringing together the world's leading specialists in aesthetic and anti-ageing medicine.
  • They wowed delegates with their pioneering research and clinical innovations in bioregenerative medicine, putting EWBG at the forefront of the industry.
  • Mike Chan, known for his innovative pioneering work in stem cells and bioregenerative medicine, presented his most recent research discoveries, promising to transform how age-related illnesses are treated.
  • The presence of the 2 prominent speakers at AMWC 2024 demonstrates EWBG's dedication to advancing medical sciences for the benefit of humanity.

Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows

Retrieved on: 
Thursday, March 28, 2024
Pesticide, Sensitivity, Xenobiotic, Collaborative writing, Prevalence, ADHD, Cell, Risk, Inflammation, Patient, SAN, School, Anglo-French Wars, Tissue, Research, Miller, Child, Breast, Virus, University, Wane, Doctor of Philosophy, Pregnancy, Causality, Attention deficit hyperactivity disorder, Gulf War, B cell, EPA, CDC, University of Texas System, Fire, Toxicology, Workforce, Public health, TILT, Spectrum, Family, Histamine, Vaccine

SAN ANTONIO, March 27, 2024 /PRNewswire-PRWeb/ -- Autism and attention deficit hyperactivity disorder (ADHD) may be preventable if parents avoid toxic exposures and adopt interventions such as environmental house calls, according to a published study led by researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio).

Key Points: 
  • The findings build on a 2015 study by UT Health San Antonio that first linked chemical intolerance in patients with the risk of their children developing autism and ADHD.
  • "Up to now, most interventions have been behavioral or medical, after a child is diagnosed."
  • Still, they wrote, "The implications of this study, if confirmed, could be significant for preventive measures and early intervention strategies in families with parental chemical intolerance.
  • And the prevalence of ADHD has risen to one in eight children, also according to the CDC.

Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium

Retrieved on: 
Tuesday, March 26, 2024
Well, Dicarboxylic acid, University, Culture, B cell, Ajinomoto, Growth, Cell, Drug discovery, Biomedical Research, Active ingredient, Good manufacturing practice, Research, GMP, University of Tokyo, Regenerative medicine, API, Good, Amino acid, Multimedia, IPSC, Fine chemical

TOKYO, March 26, 2024  /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium. The enhanced version of its widely used StemFit™ products is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC) and meet the Good Manufacturing Practice (GMP) standards for Active Pharmaceutical Ingredients (API).

Key Points: 
  • TOKYO, March 26, 2024 /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium.
  • The product line-up of StemFit™ is ideal for regenerative medicine, drug discovery and disease modeling.
  • Additionally, it also enhances further manufacturing of cellular medicines, ensuring superior performance and reliability in iPSC culture.
  • The Group's expertise in GMP API production contributes to the superior performance of the StemFit™ medium, ensuring it meets the highest industry standards.

Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats

Retrieved on: 
Monday, March 25, 2024
Research, ESC, Bioreactor, B cell, Regeneration, Neurology, Rat, Cell, Osteogenesis imperfecta, Assistant, Cardiology, Critical Care Medicine (journal), Patient, American Journal, DNA, Pharmacist, Manuscript, Cancer, University, Hope, Doctor of Philosophy, Lung transplantation, MD, Biostatistics, Respiratory failure, Cas9, CRISPR, Stem cell, Premature, Research institute, College of Engineering (KNUST), Medicine, Nursing, Animal

PHOENIX, March 25, 2024 /PRNewswire/ -- Research conducted at the Phoenix Children's Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.

Key Points: 
  • The critical differentiating factor with this study is researchers incorporated CRISPR-Cas9, a unique genome editing technology that allows researchers to change genomes by altering sections of the DNA sequence.
  • Modifications of rat embryos by CRISPR-Cas9 allowed the formation of lung tissues consisting of almost all mouse lung cells.
  • This is one of many recent accolades for the Phoenix Children's Research Institute.
  • The Phoenix Children's Research Institute at the University of Arizona College of Medicine –Phoenix launched in May 2023, formalizing a longstanding research collaboration between the health system and the University of Arizona College of Medicine – Phoenix.

Advanced Map of Human Blood Stem Cells Could Guide Highly Targeted Leukemia Care

Retrieved on: 
Thursday, March 21, 2024
Glycophorin A, B cell, Gene, Flow cytometry, Gene expression, Cell, AML, Mechanics, Patient, Biomarker, Research, RNA, Leukemia, Doctor of Philosophy, AUC, CD326, Antibody, Machine learning, Game theory, Blood, Hematology, Bone marrow, Atlas, Vaccine

CINCINNATI , March 21, 2024 /PRNewswire/ -- Thanks to an unusual application of game theory and machine learning technology, a large team of scientists led by experts at Cincinnati Children's has published the world's most detailed "atlas" of the many types of stem cells and early progenitors involved in producing human blood from diverse donors.

Key Points: 
  • The team has identified more than 80 distinct subsets of hematopoietic stem and progenitor cells (HSPCs) – early-stage cells that kick off production of mature red cells, white cells and other elements of our complex blood system.
  • Among the team's key findings:
    Mixing a new "cocktail" of 132 antibodies that can target surface proteins on HSPCs and related cells.
  • Testing demonstrated that the new mix outperforms commercial products for profiling human bone marrow cells.
  • One of the most immediate potential applications of the new stem cell atlas centers on how treatment centers monitor patients receiving therapies for leukemia.

10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

Retrieved on: 
Thursday, March 21, 2024
B cell, Oncogene, Tissue, Research, Tumor microenvironment, Cell membrane, University, Genomics, Escape Room, Medical imaging

PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.

Key Points: 
  • PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications.
  • These new products expand the breadth of the Xenium single cell spatial analysis menu.
  • The Xenium In Situ Cell Segmentation Kit improves the determination of cell boundaries by using a stain and algorithmic technique developed and validated through custom-trained machine learning models.
  • State-of-the-art, custom-built algorithm: Obtain more accurate cell segmentation with an advanced AI algorithm specifically trained on real-world Xenium cellular and tissue data.

Biosion to Present Three Posters at the 2024 AACR Meeting

Retrieved on: 
Thursday, March 21, 2024
HER2, Malignancy, CD16, Trastuzumab, Head, B cell, Cancer, Patient, BTN3A3, IND, AACR, BTN3A1, Cholangiocarcinoma, CD40, NK, Vaccine

"We are thrilled to present three posters at the AACR annual meeting.

Key Points: 
  • "We are thrilled to present three posters at the AACR annual meeting.
  • BSI-111 binds specifically to CD16a without recognizing CD16b and binds the two allelic variants of CD16A - 158F and 158V with similar high affinity.
  • Additionally, Biosion's partner, CTTQ Pharma, OBI Pharma and Pyxis Oncology, will also be presenting posters at the AACR meeting.
  • In 2019, Biosion licensed Greater China rights of BSI-038 to CTTQ and retains all rights for development and commercialization in the rest of the world.

Next Mission to Space Station Carries Research on Vision Loss Treatments and Earth-Viewing Technology

Retrieved on: 
Wednesday, March 20, 2024
Janus, LEO, B cell, Falcon 9, Commercial Resupply Services, Medication, University, Eli Lilly and Company, MassChallenge, Patient, ISS National Lab, Research, International Space Station, Boeing, 3D, Astrobee, CRS, Life, Butler University, CSIRO, Argus, Arthritis, Laboratory, NASA, ISS, Cartilage, AMD, Therapy, PIL, SpaceX, Redwire, Defense, Health, Communications satellite

CAPE CANAVERAL, Fla., March 20, 2024 /PRNewswire/ -- The next resupply mission to the International Space Station (ISS) will carry more than 40 payloads sponsored by the ISS National Laboratory®, including in-space production applications projects, technology demonstrations, life science experiments, and student-led inquiries. These investigations, launching on SpaceX's 30th Commercial Resupply Services (CRS) mission, funded by NASA, aim to improve life on Earth through space-based research and foster a sustainable economy in low Earth orbit (LEO).

Key Points: 
  • Results from this research could lead to improved therapeutics to treat an array of conditions.
  • A collaboration between Boeing and CSIRO (an Australian government agency responsible for scientific research) will test the ability of a Multi-Resolution Scanner to create 3D maps of the space station.
  • Once ArgUS is installed, it will host multiple payloads on this mission, including SpaceTV-1, an optical video system designed to livestream high-definition views of Earth and the space station.
  • An investigation from biopharmaceutical company Oculogenex will use the space station to test a novel gene therapy to prevent and possibly even reverse vision loss from age-related macular degeneration (AMD).

FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy

Retrieved on: 
Monday, March 18, 2024
Encephalitis, Locomotion, Brain, B cell, Bone marrow, Cell, Dietary supplement, Nervous system, Risk, Patient, Public, Urinary tract infection, Animal, Metachromasia, DSM-IV codes, Peripheral nervous system, Viral, Human services, Hope, Death, Quality of life, Atidarsagene autotemcel, Rash, Therapy, Metachromatic leukodystrophy, Natural history, Fever, MLD, Heated tobacco product, Safety, Disability studies, Cosmetics, Health, Vaccine, Food, Swelling, FDA, Liver, Multimedia, ARSA, Pharmaceutical industry

Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system.

Key Points: 
  • Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system.
  • The stem cells are collected from the patient and modified by adding a functional copy of the ARSA gene.
  • In children with MLD, treatment with Lenmeldy significantly reduced the risk of severe motor impairment or death compared with untreated children.
  • Eighty five percent of the children treated had normal language and performance IQ scores, which has not been reported in untreated children.